FGAM
SKYE icon

Financial Gravity Asset Management’s Skye Bioscience SKYE Stock Holding History

Financial Gravity Asset Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$2.54K Buy
+1,600
New +$4.37K ﹤0.01% 792
2024
Q2 		$12.8K Buy
+1,600
New +$19K ﹤0.01% 444

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Financial Gravity Asset Management's SKYE Position: Q1 2025 in Review

Financial Gravity Asset Management opened a new position in Skye Bioscience (SKYE) in Q1 2025: 1,600 shares worth $2.54K. The stake represents ﹤0.01% of the portfolio and ranks #792 among its holdings. This is a return to the name: Financial Gravity Asset Management previously reported a position in SKYE as recently as Q2 2024.

Financial Gravity Asset Management first reported a position in SKYE in Q2 2024 and has held it in 2 quarters since. The position peaked at $12.8K in Q2 2024. 75 funds tracked by Wall St. Rank hold SKYE as of Q1 2025.

  • Financial Gravity Asset Management held 1,600 shares of Skye Bioscience worth $2.54K as of Q1 2025.
  • Skye Bioscience was a new Financial Gravity Asset Management position in Q1 2025.
  • Skye Bioscience made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q1 2025, its #792 holding.
  • Financial Gravity Asset Management first reported a position in Skye Bioscience in Q2 2024 and has held it in 2 quarters since.
  • Financial Gravity Asset Management's Skye Bioscience position peaked at $12.8K in Q2 2024.
  • 75 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2025.

Based on Financial Gravity Asset Management's 13F filing for Q1 2025, filed 30 Apr 2025.